----
Current ValuationThe current P/E ratio is -29.47, below the reasonable range, cheaper than 86.42% of the time in the past 5 years, and the industry ranks 64/84, the industry Median 21.22.
-29.47xP/E
¥38.39Stock price
¥-1.30Earnings per share
-29.47xP/E
Stock price¥38.39Earnings per share¥-1.30
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 25.35x
- Typical range
- -26.22x–160.31x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 21.22x
023466992
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 21.22x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
300122SZZHIFEI-BIOL | -2.19x | 91.91% | ¥30.83B |
688180SHJunshi Biosciences | -71.47x | 81.90% | ¥30.64B |
603392SHWantai Biological | -64.30x | 22.02% | ¥29.30B |
688192SHDizal Pharmaceutical | -43.15x | 255.85% | ¥25.76B |
300676SZBGI Genomics | -29.47x | 118.23% | ¥16.06B |
688520SHSinocelltech | -16.59x | 171.21% | ¥14.88B |
688319SHOlymvax Biopharmaceuticals | -321.71x | 227.87% | ¥10.30B |
688765SHHEALTHGEN BIOTECH | -72.15x | -- | ¥10.22B |
688806SHTrinomab Pharmaceutical | -21.90x | -- | ¥9.86B |
688062SHMabwell | -9.08x | 37.63% | ¥9.54B |
300204SZStaidson BioPharm | -92.34x | -- | ¥9.19B |
688137SHNovoprotein | -93.51x | -- | ¥9.05B |
688443SHGenrix Bio | -14.90x | 32.19% | ¥8.38B |
688382SHInventisBio | -20.05x | 5.45% | ¥7.60B |
002030SZDAJY | -9.95x | -- | ¥7.40B |
688177SHBIO-THERA | -15.90x | 2.47% | ¥7.01B |
300294SZBOYA BIOLOGY | -41.65x | 281.82% | ¥6.99B |
688759SHBeBetter Med | -34.00x | 12.50% | ¥6.72B |
688276SHBCHT | -32.67x | 66.67% | ¥6.53B |
002038SZSL PHARM | -6.14x | -- | ¥5.15B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
